Julve Josep, Genua Idoia, Quifer-Rada Paola, Yanes Óscar, Barranco-Altirriba Maria, Hernández Marta, Junza Alexandra, Capellades Jordi, Granado-Casas Minerva, Alonso Núria, Castelblanco Esmeralda, Mauricio Didac
Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), 08041 Barcelona, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Barcelona, Spain.
Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), 08041 Barcelona, Spain; Department of Endocrinology & Nutrition, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain.
Diabetes Res Clin Pract. 2023 Mar;197:110578. doi: 10.1016/j.diabres.2023.110578. Epub 2023 Feb 16.
To uncover novel candidate metabolomic and lipidomic biomarkers in newly-diagnosed type 1 diabetes (T1DM) after achieving optimal glucose control.
Comprehensive lipidomic and metabolomic analysis was performed in serum of 12 adults with T1DM at onset and after achieving optimal glycemic control (HbA1c < 7 %) (after 2-6 months).
After intensive therapy, subjects (mean age 25.2 years, 58.3 % men) showed decreases in blood glucose (p < 0.001), HbA1c [11.5 % (9.2-13.4) to 6.2 % (5.2 - 6.7); p < 0.001] and changes in 51 identified lipids. Among these changes, we found that triglycerides (TG) containing medium chain fatty acids (TG45:0, TG47:1), sphingomyelins (SM) (SM(d18:2/20:0), SM42:4)), and phosphatidylcholines (PC) (PC(O-26:2), PC(O-30:0), PC(O-32:0), PC(O-42:6), PC(O-44:5), PC(O-38:3), PC(O-33:0), PC(O-46:8), PC(O-44:6), PC(O-40:3), PC(O-42:4), PC(O-46:7), PC(O-46:6), PC(O-44:5), PC(O-42:3), PC(O-44:4)) decreased; whereas PC(35:1), PC(37:1) and TG containing longer chain fatty acids (TG(52:1), TG(55:7), TG(51:2), TG(53:3), TG52:2), TG(53:2), TG(57:3), TG(61:3), TG(61:2) increased. Further, dihydro O-acylceramide (18:1/18:0/16:0), diacylglycerophosphoethanolamine (PE(34:1)), diacylglycerophosphoinositol (PI(38:6), and dihydrosphingomyelins (dihydroSM(36:0), dihydroSM(40:0), dihydroSM(41:0), dihydroSM(42:0)) increased. Uric acid, mannitol, and mannitol-1-acetate levels also increased.
Our data uncovered potential favorable changes in the metabolism of glycerophospholipids, glycerolipids, and sphingolipids in new-onset T1DM after achieving optimal glycemic control. Further research on their potential role in developing diabetes-related complications is needed.
在新诊断的1型糖尿病（T1DM）患者实现最佳血糖控制后，发现新的候选代谢组学和脂质组学生物标志物。
对12例成年T1DM患者发病时及实现最佳血糖控制（糖化血红蛋白<7%）（2 - 6个月后）的血清进行全面的脂质组学和代谢组学分析。
强化治疗后，受试者（平均年龄25.2岁，男性占58.3%）血糖降低（p<0.001），糖化血红蛋白从[11.5%（9.2 - 13.4）降至6.2%（5.2 - 6.7）；p<0.001]，51种已鉴定的脂质发生变化。在这些变化中，我们发现含有中链脂肪酸的甘油三酯（TG45:0、TG47:1）、鞘磷脂（SM）（SM(d18:2/20:0)、SM42:4））和磷脂酰胆碱（PC）（PC(O-26:2)、PC(O-30:0)、PC(O-32:0)、PC(O-42:6)、PC(O-44:5)、PC(O-38:3)、PC(O-33:0)、PC(O-46:8)、PC(O-44:6)、PC(O-40:3)、PC(O-42:4)、PC(O-46:7)、PC(O-46:6)、PC(O-44:5)、PC(O-42:3)、PC(O-44:4)）减少；而PC(35:1)、PC(37:1)以及含有较长链脂肪酸的甘油三酯（TG(52:1)、TG(55:7)、TG(51:2)、TG(53:3)、TG52:2)、TG(53:2)、TG(57:3)、TG(61:3)、TG(61:2)）增加。此外，二氢O-酰基神经酰胺（18:1/18:0/16:0）、二酰基甘油磷酸乙醇胺（PE(34:1)）、二酰基甘油磷酸肌醇（PI(38:6)）以及二氢鞘磷脂（二氢SM(36:0)、二氢SM(40:0)、二氢SM(41:0)、二氢SM(42:0)）增加。尿酸、甘露醇和甘露醇-1-乙酸水平也升高。
我们的数据揭示了新发病的T1DM患者在实现最佳血糖控制后，甘油磷脂、甘油olipids和鞘脂代谢中潜在的有利变化。需要进一步研究它们在糖尿病相关并发症发生发展中的潜在作用。
